SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
|Articles|February 1, 2003
Exploring Earth's Mysteries
Author(s)Karen Nash
There was little in his childhood in Washington, D.C., to indicate that Haines Ely's future would take him to a career as a dermatologist/dermatopathologist, with a weekly radio talk show that deals often in metaphysics and alternative medicines. He also leads trips to visit a faith healer in Brazil.
Advertisement
Advertisement
Related to this article
Tina Bhutani-Jacques, MD, explored how disease location, prior treatment response, and patient preference shape topical treatment decisions across 3 plaque psoriasis cases.
Benjamin Ungar, MD, moderated a recent Dermatology Times Case-Based Roundtable event on how to define severity, choose among JAK inhibitors, and monitor patients with alopecia areata.
Clinicians at a Dermatology Times Case-Based Roundtable, moderated by Chesahna Kindred, MD, debated when to escalate to oral JAK inhibitors for alopecia areata and how to counsel patients on timing, monitoring, and safety.
The joint AAD-HSF guideline issues 37 recommendations, including strong support for adalimumab, bimekizumab, infliximab, and secukinumab.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
Dermatology’s growing focus on skin longevity demands clear definitions, validated outcomes, and rigorous evidence beyond anti-aging claims.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Advertisement
Advertisement
Trending on Dermatology Times
1
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
2
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
3
Nonsteroidal Topicals Guide Special-Site Psoriasis Treatment Decisions
4
Severity, Response Timing, and Lab Monitoring in Alopecia Areata Care
5